A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

Medicare spending on some diabetes drugs, including popular treatments such as Ozempic, surged nearly five-fold to $35.8 ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.

Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food ...

The Trump administration, perhaps surprisingly, chose to defend the legality of the Inflation Reduction Act’s (IRA’s) drug ...

The automakers are using software and AI to make vehicles of tomorrow more collaborative, working alongside passengers. The Singapore-based company expects to raise $2.58 billion from the sale of its ...

Eli Lilly (LLY) and Novo Nordisk (NVO) to dominate as TD Cowen lifts 2030 sales forecast for GLP-1 class of obesity/ diabetes ...

Trump’s tariff warning has created shockwaves through India’s pharmaceutical industry, which supplied almost half of ...

UnitedHealth Group slid after The Wall Street Journal reported that the Department of Justice was probing the insurance giant's Medicare billing practices. The company, which had already faced a ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and ...

The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail ...